Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00300885 · ClinicalTrials.gov registry record · Phase 3
A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
A Phase 3 study, sponsored by Bayer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 926
- Enrollment target
NCT00300885: Clinical Trial Phase 3 study, sponsored by Bayer.
NCT00300885 is a Phase 3 study that was terminated before completion, run by Bayer. The registered enrollment target is 926 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (20% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00300885, a Phase 3 study, was terminated before completion, sponsored by Bayer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 926 participants
- Enrollment target
Study Summary
A randomized controlled trial comparing safety and efficacy of carboplatin and paclitaxel plus or minus sorafenib in chemonaive patients with stage III-IV non-small cell lung cancer.
Primary Outcome
Overall survival determined as the time (days) from the date of randomization at start of study to the date of death, due to any cause. Outcome measure was assessed regularly, i.e. every 3 weeks during study treatment and every 3 months during post-treatment.
Interventions
- DRUG Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel
- DRUG Carboplatin plus Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 926 participants |
| Start Date | 2006-02 |
| Est. Completion | 2009-02 |
| Phase | Phase 3 |
Why NCT00300885 stopped before completion
NCT00300885 is an interventional study that assigns participants to a tested intervention. The registered 926 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (20% higher).
The record links to 0 conditions, and to 2 interventions - of which Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel is the first listed.
NCT00300885 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00300885 about?
NCT00300885 is a clinical study titled "A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)". A randomized controlled trial comparing safety and efficacy of carboplatin and paclitaxel plus or minus sorafenib in chemonaive patients with stage III-IV non-small cell lung cancer.
What is the current status of trial NCT00300885?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 926 participants. The study started on 2006-02. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00300885?
The interventions under investigation include: Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel (DRUG), Carboplatin plus Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT00300885?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00300885's enrollment target sits among peer trials
926 341st of 2000 higher than 1,660 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03995082 · 925 participants · NA
Breast Cancer Patient Engagement With Patient Reported Outcome Measure Survey
- NCT06378541 · 928 participants · NA
Smartphone App Enhanced Facilitation Among Veterans in a Mental Health Inpatient Setting (Project HOPE)
- NCT04692493 · 924 participants · Phase 3
Ra-pro Pragmatic Trial
- NCT05656807 · 924 participants · NA
Evaluation of Child Care Staff Weight Management Program
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia